1. Home
  2. HALO
  3. HALO News

Latest Halozyme Therapeutics Inc. (HALO) News on April 19, 2025

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity
HALO

Simply Wall St.

3 days ago

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity

HALO

Argus Research

4 days ago

HALO: Raising target price to $67.00

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market
HALO

Investor's Business Daily

8 days ago

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market

HALO

MT Newswires

8 days ago

Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
HALO

PR Newswire

9 days ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

HALO

MT Newswires

10 days ago

Halozyme Says European Commission Approves Darzalex Co-Formulated With Enhanze to Treat Multiple Myeloma

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
HALO

PR Newswire

10 days ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

HALO

Argus Research

11 days ago

HALO: Rating increased to a BUY

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
HALO

Zacks

11 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

HALO

MT Newswires

12 days ago

Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
HALO

PR Newswire

12 days ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

HALO

Argus Research

18 days ago

HALO: Lowering target price to $65.00

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
HALO

PR Newswire

19 days ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
HALO

Zacks

22 days ago

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?
HALO

Zacks

24 days ago

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

HALO

Argus Research

25 days ago

HALO: Raising target price to $68.00

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
HALO

Zacks

a month ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
HALO

Zacks

a month ago

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Halozyme Joins the $1 Billion Club
HALO

FX Empire

a month ago

Halozyme Joins the $1 Billion Club

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue
HALO

Investor's Business Daily

a month ago

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
HALO

Zacks

a month ago

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?

HALO vs. AMGN: Which Stock Is the Better Value Option?
HALO

Zacks

a month ago

HALO vs. AMGN: Which Stock Is the Better Value Option?

Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why
HALO

Insider Monkey

a month ago

Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why

AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.
HALO

Barrons.com

a month ago

AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.

High Growth Tech Stocks To Watch In US March 2025
HALO

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In US March 2025

HALO

MT Newswires

a month ago

Update: Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
HALO

The Wall Street Journal

a month ago

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
HALO

Zacks

a month ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

HALO

MT Newswires

a month ago

Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version

HALO

Argus Research

2 months ago

HALO: What does Argus have to say about HALO?

HALO

MT Newswires

2 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,260,681, According to a Recent SEC Filing

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
HALO

PR Newswire

2 months ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

HALO

Argus Research

2 months ago

HALO: What does Argus have to say about HALO?

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
HALO

Zacks

2 months ago

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
HALO

Zacks

2 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Halozyme Therapeutics Full Year 2024 Earnings: Beats Expectations
HALO

Simply Wall St.

2 months ago

Halozyme Therapeutics Full Year 2024 Earnings: Beats Expectations

HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
HALO

Zacks

2 months ago

HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth

HALO

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Halozyme Therapeutics Inc Earnings Call

Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ...
HALO

GuruFocus.com

2 months ago

Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ...

HALO

Argus Research

2 months ago

HALO: Raising target price to $61.00

Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say
HALO

Zacks

2 months ago

Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates
HALO

Zacks

2 months ago

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates

HALO

Associated Press Finance

2 months ago

Halozyme Therapeutics: Q4 Earnings Snapshot

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
HALO

Investor's Business Daily

2 months ago

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90

HALO

MT Newswires

2 months ago

Halozyme Therapeutics Q4 Non-GAAP EPS, Revenue Increase

Incyte Stock Sees Relative Strength Rating Rise To 71
HALO

Investor's Business Daily

2 months ago

Incyte Stock Sees Relative Strength Rating Rise To 71

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
HALO

Zacks

2 months ago

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
HALO

Zacks

2 months ago

HALO Gears Up to Report Q4 Earnings: Here's What You Should Know

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
HALO

Zacks

2 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

Here's How Much You'd Have If You Invested $1000 in Halozyme Therapeutics a Decade Ago
HALO

Zacks

2 months ago

Here's How Much You'd Have If You Invested $1000 in Halozyme Therapeutics a Decade Ago

Halozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now
HALO

Insider Monkey

2 months ago

Halozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now

Halozyme Stock Climbs Back After 2024 Sneak Peek As Earnings Loom
HALO

Investor's Business Daily

2 months ago

Halozyme Stock Climbs Back After 2024 Sneak Peek As Earnings Loom

HALO

Argus Research

2 months ago

HALO: Raising target price to $60.00

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
HALO

PR Newswire

2 months ago

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

HALO

MT Newswires

3 months ago

Halozyme Therapeutics Says Non-Small Cell Lung Cancer Treatment Gets Positive Opinion in Europe

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
HALO

PR Newswire

3 months ago

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
HALO

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

High Growth Tech Stocks To Watch In January 2025
HALO

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In January 2025

HALO

Argus Research

3 months ago

HALO: What does Argus have to say about HALO?

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
HALO

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
HALO

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
HALO

Zacks

3 months ago

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

HALO

Argus Research

3 months ago

HALO: Raising target price to $59.00

BeiGene Stock Meets 80-Plus RS Rating Benchmark
HALO

Investor's Business Daily

3 months ago

BeiGene Stock Meets 80-Plus RS Rating Benchmark

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
HALO

Zacks

3 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
HALO

Zacks

3 months ago

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

HALO

Argus Research

3 months ago

HALO: Raising target price to $57.00

BridgeBio Pharma Stock Earns 87 RS Rating
HALO

Investor's Business Daily

3 months ago

BridgeBio Pharma Stock Earns 87 RS Rating

5 Biotech Stocks Worth Adding to Your Portfolio in 2025
HALO

Zacks

3 months ago

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
HALO

Zacks

3 months ago

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
HALO

Zacks

3 months ago

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
HALO

Zacks

3 months ago

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
HALO

Zacks

3 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
HALO

Zacks

3 months ago

HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up

Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?
HALO

Zacks

3 months ago

Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
HALO

Zacks

3 months ago

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

SpringWorks Therapeutics Stock Gets A RS Rating Lift
HALO

Investor's Business Daily

3 months ago

SpringWorks Therapeutics Stock Gets A RS Rating Lift

HALO

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Premarket Wednesday

HALO

MT Newswires

3 months ago

Sector Update: Health Care

HALO

MT Newswires

3 months ago

Halozyme Therapeutics Raises 2025 Guidance; Shares Up Pre-Bell

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
HALO

PR Newswire

3 months ago

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

HALO

MT Newswires

3 months ago

Halozyme Therapeutics Insider Sold Shares Worth $500,060, According to a Recent SEC Filing

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
HALO

Zacks

3 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
HALO

Zacks

3 months ago

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical
HALO

Zacks

3 months ago

Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical

These 4 Stocks Boast Impressive Interest Coverage Ratios
HALO

Zacks

3 months ago

These 4 Stocks Boast Impressive Interest Coverage Ratios

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
HALO

PR Newswire

3 months ago

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

Exploring 3 Prominent High Growth Tech Stocks In The United States
HALO

Simply Wall St.

4 months ago

Exploring 3 Prominent High Growth Tech Stocks In The United States

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
HALO

Zacks

4 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
HALO

PR Newswire

4 months ago

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
HALO

PR Newswire

4 months ago

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
HALO

PR Newswire

4 months ago

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
HALO

Zacks

4 months ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

HALO

Argus Research

4 months ago

HALO: Lowering target price to $58.00

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
HALO

Zacks

4 months ago

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)

HALO or FOLD: Which Is the Better Value Stock Right Now?
HALO

Zacks

4 months ago

HALO or FOLD: Which Is the Better Value Stock Right Now?

HALO

Argus Research

4 months ago

HALO: Lowering target price to $60.00

How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08%
HALO

Zacks

4 months ago

How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08%

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
HALO

Zacks

4 months ago

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
HALO

Zacks

4 months ago

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Share on Social Networks: